Compare Petróleo Brasileiro SA (PBR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Sana Biotechnology Inc — how do they compare? Petróleo Brasileiro SA trades at $20.95 (market cap $128.30B), while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Petróleo Brasileiro SA is far larger — about 124.6× Sana Biotechnology Inc's market cap, and Petróleo Brasileiro SA pays a 8.07% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PBR | SANA | |
|---|---|---|
Market Cap | $128.30B | $1.03B |
Sector | Technology | Health |
52-Week High | $22.03 | $5.92 |
52-Week Low | $11.54 | $2.68 |
Enterprise Value | $188.72B | $946.04M |
Dividend Yield | 8.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $20.83, up 3.53% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a low P/E of 5.26, robust net income margin of 24.52%, and record Q2 2026 earnings beating estimates. Recent news highlights regulatory approvals for new drilling in Brazil and exploration in Ghana, signaling growth potential.
Outlook is positive given low valuation, high profitability, and expansion efforts, but risks include geopolitical factors and oil price volatility. Analyst consensus leans bullish with 50% buy ratings, though the stock faces headwinds from softer crude prices and execution risks in new projects.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
